RxDoctor Payments Data

Thomas Chen, MD

Nephrology · Honolulu, HINPI 1457575417

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Nxstage Medical, Inc. at 29.3% of the total. 2025 is the largest year on record at $510, 5.0 times the $102 reported in 2019. That places this record below the midpoint for nephrology clinicians in HI, where the typical reported total is $2,126.

$1,346in general payments, 2019–2025

Across 16 payments — averaging $84.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nxstage Medical, Inc.$394
  • Apellis Pharmaceuticals, Inc.$137
  • Novartis$133
  • Takeda Pharmaceuticals U.S.A., Inc.$125
  • Travere Therapeutics, Inc.$125
  • Outset Medical Inc$124
  • plus $308 from 4 others

What the payments were for

  • Food & beverage$1,346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,346 in reported general payments places this provider in the 40th percentile of 57 nephrology providers in Hawaii.

See all nephrology providers in Hawaii

Medicare billing

Part B allowed, 2024
$18,310
Medicare patients
54
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate184$48,234
JardianceEmpagliflozin57$29,297
ProcritEpoetin Alfa34$18,410
Midodrine Hcl39$2,860
Losartan Potassium177$2,854
Calcium Acetate27$2,521
Humulin NInsulin Nph Human Isophane12$1,292
Furosemide68$1,260
Lidocaine-PrilocaineLidocaine/Prilocaine55$1,246
Fludrocortisone Acetate12$1,168
Amlodipine Besylate72$1,070
Lisinopril45$658
Allopurinol80$577
Calcitriol22$514
Atorvastatin Calcium44$467

Paid to pharmacies, not to this prescriber.

Other nephrology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →